Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

Lausanne, Switzerland – November 18, 2014 – Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs along with companion diagnostics to target unmet medical needs, announced today that new data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 26th European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) (EORTC-NCI-AACR) Annual Meeting, November 18 to 21, 2014, to be held in Barcelona.

Data featured at the EORTC-NCI-AACR symposium will include the results of the ongoing phase I study of Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Debio 1143 is an oral, small molecule inhibitor of apoptosis proteins (IAPs) that mimics the activity of the natural second mitochondrial-derived activator of caspases (SMAC). The first signs of activity that have been observed in patients with triple-negative breast cancer and platinum-refractory ovarian cancer will be reported – Abstract number 444.

Abstract number 547 will summarize the data obtained with Debio 1347/CH5183284, a highly selective, oral, fibroblast growth factor receptor (FGFR) 1, 2, 3 inhibitor. This compound is currently being evaluated in a first-in-man, phase I trial in patients with specific alterations of the FGFR genes. Strong activity of the compound in animal models with either a FGFR fusion or amplification will be disclosed.

“The present and future of oncology are in the development of targeted compounds. In addition to this, combination therapies will continue to play a crucial role in the improvement of cancer treatments. The two programs we present at EORTC-NCI-AAACR meeting address these needs”, said Jean-Maurice Dumont, Vice President, Medical Affairs at Debiopharm International. “We are very excited by these preliminary results and we believe, we may have potential new treatments able to provide improved benefit for patients suffering from solid tumors”.

About Debiopharm Group™
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit: